Navigation Links
OmniComm Systems' Awarded 4 Clinical Trials from U.S. Biotechnology Company
Date:4/5/2011

FORT LAUDERDALE, Fla., April 5, 2011 /PRNewswire/ -- OmniComm Systems, Inc. (OTC: OMCM), one of the fastest growing companies in the EDC marketplace, today announced that its TrialMaster® suite of applications and IVRS technology has been chosen by a prominent biotechnology company to manage their clinical data management and randomization needs for 4 key clinical trials.  All 4 studies, leveraging OmniComm's Software-as-a-Service (SaaS) rapid-deployment model, will be put into production by the end of May.

"We are honored to be chosen by this biotech firm to manage so many key studies," said Stephen Johnson, President & COO of OmniComm.  "Our past experience with this company, and the trust that we've built with them to get these studies up and running under such tight timelines, were pivotal in their selection of OmniComm.  We look forward to the challenge."

OmniComm has also recently become a Society for Clinical Data Management CCDM® partner, an achievement that is only bestowed upon companies that are committed to quality clinical data management and Certified Clinical Data Manager (CCDM) credentialing.  Qualifying companies must have at least 10 certified CCDMs or 25% of CDMs must have achieved certification.

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

CONTACT:
Bev Hudson
OmniComm Systems, Inc.
954-473-1254
bhudson@omnicomm.com


'/>"/>
SOURCE OmniComm Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sarah Cannon Research Institute Selects OmniComm Systems Electronic Data Capture Solution, TrialMaster(TM), for Clinical Trials Management
2. Amarex Clinical Research Selects OmniComm Systems to Provide eClinical Solutions for Phase III Medical Device Study and Joins OmniComms CRO Preferred Program
3. Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease
4. OmniComm Systems, Inc. Announces 2010 First Half Results
5. OmniComm Systems Announces Auditor Change
6. OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting
7. Beardsworth® Selects OmniComm Systems® AE Reporting System
8. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
11. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
(Date:4/18/2017)... MINNEAPOLIS , April 18, 2017 Cogentix ... focused on providing the Urology, Uro/Gyn and Gynecology markets ... for the first quarter ended March 31, 2017 after ... The Company will host a conference call ... day on Tuesday, May 2, 2017 at 4:30 p.m. ...
Breaking Medicine Technology:
(Date:4/22/2017)... , ... April 22, 2017 ... ... of Eastern Pennsylvania has named PROSHRED® Security of Philadelphia its “Woman-Owned ... PROSHRED® Philadelphia specializes in providing information destruction , recycling, and ...
(Date:4/21/2017)... ... April 21, 2017 , ... An April 10 article ... of ancient teeth, which reveal a great deal about prehistoric ice-age dental practitioners and ... may have been used to remove decayed dental matter, and that teeth were then ...
(Date:4/21/2017)... ... April 21, 2017 , ... Chicago plastic surgeon, Dr. Anil R. Shah, ... is a benign bony lump located on the forehead usually attributed to a facial ... sight and pain. Dr. Shah has discovered an approach that is minimally invasive. He ...
(Date:4/21/2017)... ... 2017 , ... Dudnyk has announced the launch of its new brand identity, ... potential of specialty and orphan brands can only be achieved when the needs and ... Effect is at the heart of a true partnership between our agency and our ...
(Date:4/21/2017)... Hong Kong (PRWEB) , ... April 21, 2017 , ... ... Printing (U3DP), the first 3D printing facility among higher education institutions in Hong Kong ... 3D printing, in terms of the range and quantity of facilities in Hong Kong. ...
Breaking Medicine News(10 mins):